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Abstract
Barth syndrome (BTHS) is an ultra-rare, X-linked recessive disorder characterized by car-
dio-skeletal myopathy, exercise intolerance, and growth delay. Oxygen uptake during peak
exercise (VO2peak) has been shown to be severely limited in individuals with BTHS however;
the trajectory of VO2peak from childhood to young adulthood is unknown. The objective of
this study was to describe VO2peak from childhood through young adulthood in BTHS. Meth-
ods and Materials: VO2peak over time was presented through cross-sectional (n = 33 partici-
pants) and a longitudinal analyses (n = 12 participants). Retrospective data were obtained
through maximal exercise testing on a cycle ergometer from individuals with BTHS who
were or are currently enrolled in a research study during July 2006-September 2017. Partici-
pants included in the cross-sectional analysis were divided into 3 groups for analysis: 1) chil-
dren (n = 13), 2) adolescents (n = 8), and 3) young adults (n = 12). Participants in the
longitudinal analysis had at least two exercise tests over a span of 2–9 years. Results:
VO2peak relative to body weight (ml/kgBW/min), fat-free mass (FFM) and by percent of pre-
dicted VO2peak obtained were not significantly different between children, adolescents and
young adults. VO2peak did not longitudinally change over a mean time of ~5 years in late ado-
lescent and young adult participants with repeated tests. A model including both cardiac and
skeletal muscle variables best predicted VO2peak. Conclusions: In conclusion, VO2peak rela-
tive to body weight and fat-free mass demonstrates short- and long-term stability from child-
hood to young adulthood in BTHS with some variability among individuals.
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Introduction
Barth syndrome (BTHS) is an ultra-rare (1/300,000 births [1]), X-linked recessive disorder
characterized by cardio-skeletal myopathy, exercise intolerance, neutropenia, growth delay
and 3-methylglutaconic acid [2, 3]. In BTHS, mutations in the tafazzin gene (TAZ, located on
Xq28), cause abnormal phospholipid metabolism mainly by affecting mitochondrial cardioli-
pin [4]. Tafazzin, a phospholipid-lysophospholipid transacylase, remodels monolysocardioli-
pin to tetralinoleic cardiolipin and mutations in tafazzin result in smaller and fragmented
mitochondria [5], disruptions in mitochondrial supercomplexes[6], instability in the mito-
chondrial inner membrane necessary for ATP production [7], and markedly reduced respira-
tory capacity [5].
Maximum oxygen uptake (VO2max), a concept first proposed by Hill et al. in 1923 [8, 9], is
defined as the highest rate of oxygen uptake and utilization by the body during intense, maxi-
mal exercise that no further increases in work rate bring on additional rises in VO2 (i.e. pla-
teau) [10]. Peak VO2 (VO2peak), directly reflective of VO2max, is the highest value of VO2
attained upon an incremental or other high-intensity exercise test, designed to bring the sub-
ject to the limit of tolerance[11]. VO2peak is a measure that combines cardiovascular and skele-
tal muscle oxidative function (i.e. Fick equation: oxygen uptake = cardiac output x arterio-
venous oxygen difference [12]), as well as pulmonary ventilation and diffusion capacity, and
reflects the integrated ability to transport oxygen from atmospheric air to the mitochondria to
perform work [13]. VO2peak is reliably measured by indirect calorimetry [14, 15] during
graded, maximal exercise, typically performed on a treadmill or cycle ergometer, and is rou-
tinely obtained in the clinic and research settings. After adjusting for age and other risk factors,
VO2peak is one of the best predictors of cardiovascular [16, 17] and overall mortality [18, 19] in
adults and is routinely used in the diagnosis of mitochondrial disease [20, 21].
Our group previously demonstrated severe impairments in VO2peak in individuals with
BTHS that was due to a combination of cardiac and skeletal muscle oxygen extraction dysfunc-
tion [22]. We also have shown impaired skeletal muscle oxidative function in children, adoles-
cents and young adults with BTHS that was strongly correlated with reductions in VO2peak
[23]. Due to the integrative nature of VO2peak in reflecting both cardiac function and skeletal
muscle mitochondrial capacity, and the documented cardio-skeletal impairments in individu-
als of varying ages with BTHS, VO2peak might be an ideal clinical outcome measure for inter-
ventional trials in this population. Therefore, establishing the time course of potential changes
in VO2peak with age is important in its validation as a clinical outcome measure. However; the
time course of VO2peak in BTHS is not known.
Rises in absolute VO2peak (L/min) during childhood through young adulthood in healthy,
unaffected individuals corresponds strongly to increases in physical growth[24]. However;
VO2peak relative to body (ml/kg/min) weight generally remains stable from late childhood
through young adulthood in healthy, unaffected individuals[25, 26]. Although the trajectory of
VO2peak across the life span is not known in BTHS, cross-sectional data from the six-minute
walk test suggests that cardiorespiratory fitness is higher in children and adolescents compared
to young adults and is inversely associated with age in those affected by BTHS[27]. As the six-
minute walk test has been shown to be associated with VO2peak in healthy, unaffected individu-
als[28], these data suggest that VO2peak relative to body weight might decline with advancing
age in individuals with BTHS.
The overall objective of the study was to describe VO2peak from childhood through young
adulthood individuals with BTHS. Our secondary objective was to examine the relationships
between cardiac and skeletal muscle oxidative function and VO2peak in those with BTHS. We
hypothesized that VO2peak would be the highest in children and adolescents compared with
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young adults with BTHS and VO2peak would longitudinally decline over time in participants
with serial exercise tests.
Materials and methods
Study design
Cross-sectional analysis. Retrospective data were obtained from individuals with BTHS
who were [22, 23, 29] or are currently enrolled (NCT#011629459) in a research study from
July 2006-September 2017. All research was approved by the Human Studies Committees at
Washington University in St. Louis or the University of Florida. All child participants provided
written assent and adult participants and parents of child participants provided written con-
sent to participation. Participants with BTHS (n = 33) were divided into 3 groups for analysis:
1) children (n = 13, ages 10–15 yrs), 2) adolescents (n = 8, ages 17–21 yrs), and 3) young adults
(n = 12, ages 23–32 yrs). Adolescence was defined as ages 17–21 yrs as puberty is typically
delayed in BTHS [2] (Table 1). Clinical trials registration: NCT01629459, NCT01625663,
NCT01194141.
All exercise tests were conducted on either an upright (12%) or recumbent (88%) cycle
ergometer (Lode, The Netherlands) with continuous metabolic measurement (Cardinal
Health, Dublin, OH (12%), ParvoMedics, Sandy, UT (88%)) and 12-lead ECG monitoring. For
each exercise test, participants cycled at a pedaling rate of 60 revolutions/min. Cycle ergometer
resistance for each exercise test began at 10–20 watts and was increased each minute by 5–20
watts until volitional exhaustion. Exercise tests were considered to be maximal if the peak
heart rate (HR) was85% of that predicted for age (220 − age) and/or the peak respiratory
exchange ratio (RER; VCO2/VO2) was1.1 [30]. Predicted VO2max was determined as previ-
ously described [31]. Body composition (fat-free and fat mass) was measured in n = 28 partici-
pants by air-displacement plethymosgraphy (Bod Pod, COSMED, Concord, CA). Resting
cardiac function via echocardiography (n = 27) and skeletal muscle oxidative function via 31P-
magnetic resonance spectroscopy (n = 23) were measured as previously described [22, 23].
Briefly, reported skeletal muscle oxidative function variables are as follows: 1) Tau phospho-
creatine (PCr) is the resynthesis time of PCr following calf muscle exercise, and 2) Qmax linear
and 3) ATP oxidative are models that estimate skeletal muscle oxidative capacity based on
measured PCr resynthesis[23].
The majority of participants were taking cardiac medications and granulocyte colony-stim-
ulating factor (GCSF) and some were taking nutritional supplements at the time of exercise
testing (Table 2).
Longitudinal analysis. A longitudinal analysis was performed on two repeated tests in
late adolescents and young adults with BTHS (n = 12) who had 2 exercise tests that were sep-
arated by 1 year (range 2–9 years). In participants with 3 tests, only the participant’s initial
and most recently completed test were compared. No exercise test immediately followed an
exercise intervention[29] as to not to artificially affect the results. Nine (n = 9) participants
completed two exercise tests, two (n = 2) participants completed three exercise tests and one
(n = 1) participant completed four exercise tests.
Statistics
Cross-sectional Analyses: Normality of the data was analyzed by the Shapiro-Wilk test. A one-
way analysis of variance (ANOVA) with Tukey Honesty Significant Difference post-hoc pair-
wise comparisons was used to compare cross-sectional differences in demographics and exer-
cise variables between children, adolescents and young adults in normal data. A Kruskal-
Wallis ANOVA analysis with post-hoc pairwise comparison was used for non-normally
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distributed data (VO2peak in L/min only). Because this was a retrospective analysis and based
on available data, we did not perform an a priori sample size analysis. Univariate relationships
between VO2peak and cardiac and skeletal muscle oxidative function in the cross-sectional data
were examined by Pearson correlation coefficient analysis. Potential predictors of VO2peak
with biological plausibility including cardiac (peak HR, ejection fraction, fractional shortening,
global strain), skeletal muscle (Qmax linear, Tau PCr, ATP Ox), and pulmonary function
(peak ventilation) variables were entered into a backward step-wise linear regression model.
Table 1. Participant demographics, peak exercise testing and echocardiography.
Children (10–15 yr)(n = 13) Adolescents (17–21 yr) (n = 8) Young Adult (23–32 yr) (n = 12) F-statistic p-value
Age (years) 13 ± 2, 18 ± 2 28 ± 3 0.001
Height (cm) 141.9 ± 12.5, 166.7 ± 8.8 178.4 ± 7.4 0.001
Height z-score -1.6 ± 1.0 -1.2 ± 1.1
Weight (kg) 33.9 ± 12.2, 55.0 ± 13.9 67.7 ± 13.6 0.001
Weight z-score -1.9 ± 1.5 -1.8 ± 1.7
BMI 16.4 ± 3.2 19.8 ± 4.5 21.1 ± 3.2 0.007
BMI z-score -1.3 ± 1.5 -1.6 ± 2.3
FFM (kg) 29.4 ± 11.9 37.1 ± 7.7 41.1 ± 6.3 0.02
Fat Mass (kg) 6.7 ± 16.7, 22.3 ± 12.1 26.6 ± 11.1 0.001
Exercise Testing
VO2peak (L/min) 0.5 ± 0.1, 0.7 ± 0.2 0.8 ± 0.2 0.008
VO2peak (ml/kgBW/min) 14.6 ± 3.7 13.0 ± 2.9 12.0 ± 3.6 0.20
Predicted VO2max (ml/kgBW/min) 46.1 ± 0.8 44.0 ± 0.5 40.4 ± 1.0
% Predicted VO2peak 32 ± 8 29 ± 7 30 ± 9 0.78
VO2peak (ml/kgFFM/min) 17.0 ± 6.3 18.1 ± 1.3 19.1 ± 4.0 0.57
Peak Work Rate (watts) 40.4 ± 10.7 57.9 ± 16.2 60.0 ± 11.5† 0.001
Peak HR (bpm) 164 ± 22 161 ± 22 155 ± 14 0.53
% Predicted Peak HR 79 ± 11 80 ± 11 81 ± 7 0.91
Peak RER 1.3 ± 0.3 1.6 ± 0.2 1.5 ± 0.2 0.03
Ventilation (L/min) 27.4 ± 11.8 39.8 ± 12.4 40.7 ± 10.4 0.01
O2 Pulse (ml/beat) 5.4 ± 1.2 4.1 ± 1.8 4.6 ± 1.2 0.21
Resting HR (bpm) 87 ± 11 77 ± 5 78 ± 9 0.07
Resting SBP (mmHg) 101 ± 12 104 ± 9 103 ± 8 0.82
Resting DBP (mmHg) 68 ± 10 69 ± 12 67 ± 9 0.92
Peak SBP (mmHg) 116 ± 17 133 ± 18.7 128 ± 21 0.13
Peak DBP (mmHg) 73 ± 17 77 ± 12 79 ± 10 0.63
Echocardiography
Ejection Fraction (%) 62 ± 6 52 ± 11 57 ± 13 0.13
Fractional Shortening (%) 38 ± 9 33 ± 3 31 ± 7 0.11
Global Strain (%) -21 ± 2, -17 ± 1 -15 ± 3 0.001
Skeletal Muscle Oxidative Function
Tau PCr (s) 69 ± 21 93 ± 30 69 ± 13 0.11
Qmax linear model (mmol/s) 0.54 ± 0.13 0.44 ± 0.15 0.54 ± 0.09 0.32
ATP Oxidative (mM/min) 13.1 ± 4.4 11.6 ± 4.2 11.9 ± 3.5 0.75
Values are means ± SD. BMI: body mass index, FFM: fat free mass, VO2peak: volume of oxygen consumption during peak exercise, BW: body weight in kg, RER:
respiratory exchange ratio, HR: heart rate, SBP: systolic blood pressure, DBP: diastolic blood pressure, PCr: phosphocreatine, ATP: adenosine triphosphate.
: different from Adolescents,
: different from Young Adults, p<0.05.
https://doi.org/10.1371/journal.pone.0197776.t001
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Longitudinal Analysis: Comparison of repeated exercise tests in n = 12 participants were
performed using one-way repeated measures ANOVA. SPSS Statistics software (IBM Corp.,
Armonk, NY) was used to perform all statistical analyses. Data are presented as mean ± stan-
dard deviation (SD) and statistical significance was determined at p<0.05.
Results
Cross-sectional analysis
Demographics. All presented data were normally distributed except VO2peak expressed
absolutely (L/min). As expected, age, height, and weight were different between age groups.
Body mass index (BMI) and fat-free mass were greater in young adults vs. children however
were not different between children vs. adolescents or adolescents vs. young adults. Children
had lower fat mass than adolescents and young adults but fat mass was not different between
adolescents and young adults (Table 1).
Exercise testing. All participants reached an RER 1.1 and/or 85% of predicted peak
heart rate[30]. Absolute VO2peak (L/min) and peak work rate significantly increased with
advancing age group (Fig 1A,Table 1) however VO2peak was not different between groups
when expressed by body weight (ml/kg/min) (Fig 1B), fat-free mass (FFM, n = 29) (Fig 1C)
or by percent of predicted VO2max obtained (Fig 1D). Peak heart rate (HR), percent of pre-
dicted peak HR obtained, peak systolic or diastolic blood pressure, and peak oxygen pulse
(VO2peak(ml/kg/min)/HRpeak) were not different between groups. Peak respiratory exchange
ratio (RER) was higher in young adults vs. children but was not different from adolescents.
Peak ventilation (L/min) tended to be higher in young adults and adolescents vs. children
(p = 0.06) but adolescents were not different from young adults. Resting HR or blood pressure
were not different between groups (Table 1, S1 File).
Cardiac and skeletal muscle function. Resting ejection fraction and fractional shortening
were not different between groups however; global strain was significantly lower in adolescents
and young adults compared to children. Measures of skeletal muscle oxidative function (phos-
phocreatine (PCr) recovery time (Tau) and Qmax and ATP oxidative models) were not differ-
ent between groups (Table 1).
Relationships of VO2peak with cardiac and muscle function. Amongst all participants
included in the cross-sectional analysis (n = 33) using univariate analysis, VO2peak was associ-
ated with peak HR (r = 0.53) and skeletal muscle oxidative capacity (Tau: r = -0.48, p = 0.02,
Qmax: r = 0.47, p = 0.03) however was not associated with peak RER, peak work rate, peak
ventilation, or resting cardiac function (i.e. ejection fraction, fractional shortening, or strain).
VO2max relative to body weight or fat-free mass was also not associated with age (r = -0.30,
Table 2. Medications of participants.
n % of sample
Beta-Blockers 17 52
ACE Inhibitors 14 42
Cardiac Glycosides 11 33
GCSF 9 27
Amino Acids 12 48
Vitamins 9 27
Other Nutritional Supplements 5 15
n = 33. ACE: angiotensin converting enzyme, GCSF: granulocyte colony-stimulating factor.
https://doi.org/10.1371/journal.pone.0197776.t002
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p = 0.09). A linear regression model including peak HR, ejection fraction and Tau PCr best
predicted VO2peak (R
2 = 0.78, Adjusted R2 = 0.73, Collinearity Tolerance: 0.87).
Longitudinal analysis. Repeated exercise tests were performed over the span of 2 to 9
years in n = 12 participants (Fig 2). In the analysis of the initial and most recent exercise tests
in these participants, weight significantly increased and height tended to increase from initial
to most recent test. However, relative and absolute VO2peak and other cardiorespiratory exer-
cise testing variables were not different between repeated tests (Table 3, S1 File).
Discussion
This is the first study to describe peak oxygen uptake (VO2peak) across the age range in individ-
uals with BTHS. The main and novel finding of the study is that VO2peak (relative to both body
weight and fat-free mass) upon graded exercise testing in BTHS appears to be relatively stable
as a population from childhood to young adulthood, although some inter-individual variability
exists. In addition, VO2peak appears to have short-term stability (~5 years) upon repeated test-
ing in late adolescents and young adults with BTHS. Therefore, due to the short- and relative
long-term stability and the integrative nature (i.e. encompassing cardiac, skeletal muscle oxi-
dative function) of the measure, VO2peak may be an ideal clinical outcome measure for inter-
vention studies in children, adolescents and young adults in BTHS.
Fig 1. Cross-sectional data on VO2peak in children, adolescents and young adults with BTHS. A. absolute (L/min), B. relative to body weight
(kg), C. relative to fat-free mass (kg) and D. as percent predicted for age and body mass [25].
https://doi.org/10.1371/journal.pone.0197776.g001
VO2peak in Barth syndrome
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VO2peak is an integrative measure that combines the processes of cardiovascular, skeletal
muscle, pulmonary, and nervous systems to transport oxygen from atmospheric air to the
mitochondria to perform physical work [13]. It has been shown to be a strong predictor of
numerous health outcomes including cardiovascular and all-cause mortality in healthy,
Fig 2. Longitudinal data on VO2peak relative to body mass in individuals with BTHS.
https://doi.org/10.1371/journal.pone.0197776.g002
Table 3. Repeater demographics, peak exercise testing and echocardiography.
Test 1 Test 2 p-value
Age (years) 21 ± 4 26 ± 5 0.001
Height (cm) 161.9 ± 21.2 173.8 ± 12.3 0.07
Weight (kg) 47.9 ± 18.6 57.8 ± 14.0 0.02
Resting HR (bpm) 79 ± 15 80 ± 13 0.94
Resting SBP (mmHg) 98 ± 9 100 ± 6 0.77
Resting DBP (mmHg) 66 ± 5 67 ± 10 0.62
ExerciseTesting
VO2peak (L/min) 0.6 ± 0.3 0.8 ± 0.2 0.62
VO2peak (ml/kgBW/min) 12.6 ± 2.7 12.5 ± 3.6 0.91
Peak Work Rate (watts) 52.1 ± 10.4 57.5 ± 11.6 0.63
Peak HR (bpm) 147 ± 18 160 ± 15 0.37
% Predicted Peak HR 73 ± 9 82 ± 7 0.26
Peak RER 1.5 ± 0.3 1.5 ± 0.2 0.82
Ventilation (L/min) 40.3 ± 19.4 45.2 ± 11.5 0.77
Peak SBP (mmHg) 124 ± 22 127 ± 13 0.95
Peak DBP (mmHg) 75 ± 13 78 ± 9 0.56
For participants who had 2 exercise tests, data presented are the two tests with longest time period between them. Values are means ± SD (n = 14). VO2peak: volume of
oxygen uptake during peak exercise, BW: body weight in kg, RER: respiratory exchange ratio, HR: heart rate, SBP: systolic blood pressure, DBP: diastolic blood pressure.
https://doi.org/10.1371/journal.pone.0197776.t003
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unaffected adults [16–19]. We previously have shown that VO2peak is severely impaired in
BTHS that is due to both impaired cardiac function and skeletal muscle oxidative capacity [22,
23]. In the current study, VO2peak in children, adolescents and young adults was approximately
1/3 of the value predicted for age and body mass [31] indicating severe exercise impairment in
all age groups of individuals with BTHS. Expressing VO2peak relative to body weight is the
most common way of describing VO2peak but expressing VO2peak relative to fat-free mass
(although not routinely accessible) is likely a more accurate index as fat-free mass encompasses
all non-fat tissue, including heart and skeletal muscle, that is more strongly associated with
oxygen uptake than fat tissue[24]. However, similar to VO2peak relative to body weight, we did
not find differences between children, adolescents and young adults in VO2peak relative to fat-
free mass. Our data contrasts with cross-sectional cardiorespiratory fitness testing (i.e. six-
minute walk test) data in children, adolescents and young adults with BTHS. Thompson et al.
found lower cardiorespiratory fitness (compared to predicted values) in children and adoles-
cents compared young adults with BTHS and that six minute walk values were inversely asso-
ciated with age [27]. Even when children and adolescents were combined into one group
(n = 21) and compared to young adults (n = 12) in the current study (data not shown), VO2peak
relative to body weight or fat-free mass were not different (p = 0.13). The six-minute walk test
is associated with VO2peak in healthy individuals [28]; however it is possible that this relation-
ship does not exist in BTHS.
Physical growth is an important contributing factor for the physiologic responses to exer-
cise throughout development [24] and absolute VO2peak (L/min) increases from childhood
through young adulthood in healthy, non-affected individuals [32]. This increase in VO2peak
with advancing age was seen in participants with BTHS in the current study. Growth in fat-
free mass (i.e. skeletal muscle) and heart size (i.e. stroke volume) primarily mediates increases
in absolute VO2peak during development [33]. Pubertal status also has a significant effect on
VO2peak during development [34]. However, when VO2peak is normalized to body mass, the
effects of puberty have been shown to no longer exist indicating that the primary effects of
puberty are largely mediated through increases in fat-free mass [34, 35]. This is evidenced by
the finding that VO2peak relative to body weight in boys, is highest before puberty and remains
stable throughout adolescence [26]. Although VO2max was much lower than predicted for age
and body mass [31], the stability of VO2peak relative to body weight was also present in those
with BTHS in the current study. Overall, it appears that the trajectory of VO2peak in BTHS,
albeit lower, is similar to non-affected healthy individuals.
Based on the findings of the current study, we believe that VO2peak, expressed to body
weight or fat-free mass, should be considered as a potential clinical outcome measure for inter-
vention trials in BTHS. Based on the definition from the International Council for Harmonisa-
tion of Technical Requirements for Pharmaceuticals for Human Use (ICH), a clinical outcome
(‘target’ variable, primary endpoint) should be capable of providing the most clinically relevant
and convincing evidence related to the primary objective of the trial[36]. In the case of inter-
ventional trials in BTHS, it can be argued that cardiac function and alterations in physical
function (i.e. exercise intolerance) are the biggest factors influencing quality of life in those
with BTHS [37]. Moreover, since resting cardiac function (i.e. ejection fraction) falls within
normal limits in many individuals with BTHS[38], a measure (i.e. VO2peak) that incorporates
both cardiac and skeletal muscle (as well as mitochondrial) function during exercise would be
an ideal clinical endpoint in this population. In addition, VO2peak relative to body weight or
fat-free mass, does not appear to be greatly influenced by puberty [34, 35]. In the current study
we found that a model including both cardiac and skeletal muscle variables best predicted
VO2peak. This finding, along with the short- and relative long-term stability of VO2peak,
VO2peak in Barth syndrome
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suggests that VO2peak should be considered as a potential clinical outcome measure for future
clinical trials in BTHS.
Limitations
This study was a retrospective descriptive analysis of a convenience sample of participants com-
plied from studies across 11 years. Due to the retrospective nature of the study, an a priori sam-
ple size analysis to determine differences in VO2peak between age groups was not possible and
the study might be underpowered to detect differences in VO2peak between age groups. How-
ever; the sample size necessary to detect differences in VO2peak between children/adolescents
and young adults (i.e. similar to cardiorespiratory fitness differences in the Thompson et al.
study[27]), is estimated to be n>100 participants. Age groups assigned in the cross-sectional
analysis were grouped upon knowledge of delayed puberty in BTHS[2] however; Tanner staging
was not available for all participants so there might have been some overlap in pubertal status
between children and adolescents. Most exercise tests were completed on a recumbent (88% for
cross-sectional data, 68% for longitudinal data) cycle ergometer and measured by one type of
indirect calorimeter (88%, TrueOne, ParvoMedics, Sandy, UT) although there was some vari-
ability in exercise mode (upright cycle ergometer) and indirect calorimeter (Cardinal Health,
Dublin, OH). However, previously published data demonstrate no differences in physiologic
responses to peak exercise testing between upright and recumbent cycle ergometry (including
VO2peak) in individuals with cardiovascular disease[39, 40]. Although as a population, VO2peak
was stable over time, there was some inter-individual variability in VO2peak over time both in the
cross-sectional and longitudinal analyses. Worth noting, one individual in the longitudinal anal-
ysis had a significant decline in VO2max over 5 years in young adulthood and soon after under-
went heart transplantation however; this was unusual as most individuals with BTHS who have
to undergo heart transplantation are infants and toddlers [41]. Lastly, echocardiographic, mag-
netic resonance spectroscopy and body composition data were not available for all participants.
Conclusions
In conclusion, VO2peak relative to body weight and fat-free mass demonstrates short- and
long-term stability from childhood to young adulthood in BTHS with some variability among
individuals. VO2peak appears to be a reasonable clinical outcome measure in future interven-
tion trials in BTHS.
Supporting information
S1 File. Cross-sectional and repeater VO2 data in participants with Barth syndrome.
(XLSX)
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